BI 2536 (GMP)

BI 2536 (GMP) is BI 2536 produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription[4].

755038-02-9

12352005

Apoptosis; Epigenetic Reader Domain; Polo-like Kinase (PLK)

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Cancer

O=C1[C@H](N(C2=C(N1C)C=NC(NC3=CC=C(C(NC4CCN(C)CC4)=O)C=C3OC)=N2)C5CCCC5)CC

C28H39N7O3

521.65

[1]Malik N, et al. Suppression of IFN β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem J. 2015 Jun 15;468 (3) :363-72.|[2]Chen L, et al. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett. 2015 May 18;6 (7) :764-9.|[3]Steegmaier M, et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Current Biology (2007), 17 (4), 316-322.|[4]Lénárt P, et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1. Curr Biol. 2007 Feb 20;17 (4) :304-15.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-50698G/

GMP Small Molecules

No Development Reported